Indications -- Psoriasis/Chronic Inflammation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Psoriasis/Chronic Inflammation

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (319)	1/17/2003 8:19:47 AM
From: Arthur Radley	Read Replies (1) of 631

Amgen Announces Positive Results of Phase 3 ENBREL(R) Study in Psoriasis Friday January 17, 8:01 am ET THOUSAND OAKS, Calif., Jan. 17 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN - News) today announced that a phase 3 clinical study assessing the efficacy and tolerability of ENBREL® (etanercept) in the treatment of moderate to severe plaque psoriasis had positive results, achieving the primary and all key secondary endpoints. Psoriasis is an inflammatory disease affecting nearly 7 million people in the United States.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next